National Law Review December 6, 2021
Devaki Patel, David L. Rosen, Jennifer F. Walsh, Jared B. Rifis

On November 16, 2021, U.S. House Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) introduced the highly anticipated Cures 2.0 Act (H.R. 6000). Among other things, this 173-page bipartisan bill contain provisions to accelerate medical research, increase patient access to novel therapeutics, and remove current barriers to telehealth services.

This bill would also create a new agency called Advanced Research Projects Agency for Health (ARPA-H) within the National Institutes of Health (NIH). This agency would be tasked with developing novel treatments to challenging diseases such as cancer, diabetes, ALS, and Alzheimer’s. In a press release, DeGette and Upton said, “By creating ARPA-H, we will be bringing together some of our nation’s greatest minds to help find cures to these devastating...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Cures Act, FDA, Govt Agencies, Provider
What Washington wants in Cures 2.0
How ONC Can Strengthen Its HTI-1 Rule To Ensure Transparency, Fairness, And Equity In AI
Providers Take Note: The Common Agreement Version 2.0 Released
Advancing Nationwide, Trusted Health Information Networks
Cures Act tied to quicker release, access of imaging reports

Share This Article